Genmab A/S (OTCMKTS:GNMSF) Short Interest Down 20.5% in January

Genmab A/S (OTCMKTS:GNMSF) was the target of a large decline in short interest in January. As of January 31st, there was short interest totalling 80,900 shares, a decline of 20.5% from the January 15th total of 101,800 shares. Based on an average daily trading volume, of 21,300 shares, the days-to-cover ratio is presently 3.8 days.

Genmab A/S Price Performance

GNMSF stock traded up $3.35 during mid-day trading on Monday, reaching $210.97. 157 shares of the company traded hands, compared to its average volume of 6,895. The company has a market capitalization of $13.94 billion, a P/E ratio of 20.29 and a beta of 1.04. Genmab A/S has a 52-week low of $186.61 and a 52-week high of $323.02. The company has a fifty day moving average price of $206.25 and a 200-day moving average price of $229.26.

Genmab A/S (OTCMKTS:GNMSF) last posted its earnings results on Wednesday, February 12th. The company reported $5.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $5.24. Genmab A/S had a return on equity of 17.73% and a net margin of 23.49%.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.